Phase I study of concurrent selective lymph node late-course accelerated hyperfractionated radiotherapy and S-1 plus cisplatin for locally advanced oesophageal squamous cell carcinoma
- 1 April 2016
- journal article
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 89 (1060) , 20150476
Abstract
This phase I study was aimed to assess the safety and efficacy of concurrent selective lymph node (SLN) late course accelerated hyper-fractionated (LCAF) intensity modulated radiotherapy (IMRT) and S-1, Cisplatin (CDDP) for the locally advanced esophageal squamous cell carcinoma (ESCC). The total dose of SLN LCAF IMRT was 59.6Gy/34 fractions in 5.4 weeks. The concurrent chemotherapy was administrated as following: CDDP 25mg/m2 on days 1–3 and 22–24, S-1 was applied in a de-escalating dosage with a decrement of 10 mg/m2/day, from its full dose level of 80 mg/m2, orally twice daily on days 1-14 and 22-35. We inferred the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs) and recommended dose according to adverse reaction during concurrent chemo-radiotherapy (CCRT). Total 15 ESCC patients with T2-4N0-1M0-1a were enrolled into dose level 1 (80 mg/m2). In the initial 5 patients, 2 patients developed DLTs. As MTD not reached, 5 additional patients were treated with the same dose level and DLTs only occurred in one patient. The similar results were found in the last 5 patients. After CCRT, the objective response rates were 100% for primary tumors and 86.2% for metastatic lymph nodes, respectively. Totally, the observed Grade 3 toxicities during CCRT were leucopenia (20%), neutropenia (20%) and dermatitis (13.3%), and no Grade 4 toxicity occurred. The Kaplan–Meier estimated overall and progression survival rates were 86.7% and 66.7% (1-year), 73.3% and 60% (2-year), 73.3% and 60% (3-year). The concurrent SLN LCAF IMRT and chemotherapy with S-1 and CDDP was well tolerated and performed a promising efficacy. The dose of S-1 in this regimen was recommended with 80 mg/m2 orally twice daily on days 1-14, 22-35. Concurrent chemoradiotherapy with S-1 plus cisplatin exhibited encouraging results with milder toxicities, high objective response rates and ideal overall survival time.Keywords
This publication has 31 references indexed in Scilit:
- Long-term outcomes of late course accelerated hyper-fractionated radiotherapy for localized esophageal carcinoma in Mainland China: a meta-analysisDiseases of the Esophagus, 2011
- Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed, cisplatin for locally advanced esophageal squamous cell carcinomaDiseases of the Esophagus, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancerCancer Chemotherapy and Pharmacology, 2008
- Phase III Trial of Protracted Compared With Split-Course Chemoradiation for Esophageal Carcinoma: Fédération Francophone de Cancérologie Digestive 9102Journal of Clinical Oncology, 2007
- Pattern of Lymph Node Metastases in Patients with Squamous Cell Carcinoma of the Thoracic Esophagus Who Underwent Three-Field LymphadenectomyEuropean Surgical Research, 2006
- Initial metastatic, including micrometastatic, sites of lymph nodes in esophageal squamous cell carcinomaJournal of Surgical Oncology, 2004
- Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracilInternational Journal of Clinical Oncology, 2004
- INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation TherapyJournal of Clinical Oncology, 2002
- Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the EsophagusNew England Journal of Medicine, 1992